SetPoint Medical
PrivateLast Round
Series D
Aug 11, 2025
Est. Valuation
$650M
Total Funding Raised
$379.75M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
SetPoint Medical is a medical technology company that develops implantable bioelectronic devices designed to modulate neuroimmune pathways for treating chronic autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Clinical Trials
Business Model
B2B
Customer Profile
Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
SetPoint Medical Comparables
Compare SetPoint Medical with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GSK plc | 75% | |
| Nēsos Corp. | 72% | |
| Boomerang Medical | 72% |
SetPoint Medical Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Aug 11, 2025 | ||||
| Series C Extension | Aug 11, 2025 | ||||
| VC Round | Jan 19, 2023 | ||||
| Series C | Jan 19, 2023 | ||||
| Debt | Jul 13, 2021 | ||||
VC Round | Jan 27, 2021 |
Key People
Founding team and executive leadership
SetPoint Medical Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Runway Growth Capital | Debt, Series C |
| Ascendum Capital | Series D, Series C Extension |
| Sprig Equity | Series D |
| New Enterprise Associates | Series D, Series C, Series C Extension, VC Round |
| Topspin Consumer Partners | Series C Extension, Series B, Series C |
| Ally Bridge Group | Series D |
| Gilmartin Capital | Series D, Series C, Series C Extension, VC Round |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 27, 2026
Monthly visitors grew 62% MoM, from 9.4K to 15.1K.
- Jun 24, 2026
Grew 29% QoQ, from 93 to 120 employees.
Recent news
Latest coverage and updates
- recognized_asOct 7, 2026
SetPoint Medical earns Fast Company Next Big Things in Tech honoree recognition in Health and Medicine in California on Oct 7th '26
- recognized_asOct 7, 2026
SetPoint Medical earns recognition on Fast Company's 2026 Next Big Things in Tech list in California on Oct 7th '26
- is_developingJul 27, 2026
SetPoint Medical, Inc. is developing vagus nerve stimulation platforms across neurological and inflammatory indications.
SetPoint Medical Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about SetPoint Medical's valuation, stock price, and market status.
Is SetPoint Medical a public or private company?
SetPoint Medical is a private company.
What is the current stock price of SetPoint Medical?
SetPoint Medical is a private company, so its shares have no public market price. Caplight tracks SetPoint Medical's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is SetPoint Medical worth (valuation)?
SetPoint Medical's valuation is estimated at $650.0M based on funding round data.
Can I buy SetPoint Medical stock?
SetPoint Medical shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was SetPoint Medical's last funding round?
SetPoint Medical's most recent funding round was Series D on August 11, 2025.
Who are the main investors in SetPoint Medical?
Key investors in SetPoint Medical include New Enterprise Associates, Ally Bridge Group, Flare Capital Partners, Norwest Venture Partners, Viking Global Investors.
Will SetPoint Medical IPO soon?
No public IPO plans have been announced for SetPoint Medical.
How can I track SetPoint Medical secondary market activity?
Caplight tracks bids, offers, and trades in SetPoint Medical's shares on secondary markets.